lenalidomide has been researched along with Chromosome Deletion in 205 studies
*Chromosome Deletion: Actual loss of portion of a chromosome. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 43 (20.98) | 29.6817 |
| 2010's | 142 (69.27) | 24.3611 |
| 2020's | 20 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Boultwood, J; Cattan, H; Christensson, B; Emanuelsson, EK; Forsblom, AM; Hellström-Lindberg, E; Jädersten, M; Merup, M; Nilsson, L; Pellagatti, A; Samuelsson, J; Sander, B; Wainscoat, JS | 1 |
| Ali, NA; Chan, O; Komrokji, R; Lancet, J; Padron, E; Sallman, D | 1 |
| Bernard, E; Cavelier, L; Dybedal, I; Ebeling, F; Ejerblad, E; Flogegård, M; Garelius, H; Göhring, G; Grønbaek, K; Hellström-Lindberg, E; Jädersten, M; Kittang, AO; Lorenz, F; Marcher, CW; Möllgård, L; Nilsson, L; Nørgaard, JM; Öster Fernström, A; Papaemmanuil, E; Rasmussen, B; Saft, L; Tobiasson, M | 1 |
| Goede, JS; Wilk, CM | 1 |
| Aul, C; Bock, O; Buesche, G; Ebert, BL; Ganser, A; Germing, U; Giagounidis, A; Göhring, G; Kreipe, H; Ribezzo, F; Schlegelberger, B; Schneider, RK; Teoman, H | 1 |
| Beach, CL; Fenaux, P; Franco-Villalobos, C; Giagounidis, A; Hu, A; Morison, J; Pelligra, CG; Platzbecker, U; Santini, V; Tang, D | 1 |
| Arai, A; Miura, I; Sakai, H | 1 |
| Abdelmagid, M; Al-Kali, A; Badar, T; Begna, K; Elliott, MA; Fleti, F; Foran, JM; Gangat, N; Ketterling, RP; Khera, N; Pardanani, A; Reichard, KK; Singh, A; Tefferi, A | 1 |
| Fisch, SC; Jonas, BA; Qi, L; Tuscano, JM | 1 |
| Invernizzi, R | 1 |
| Aoki, Y; Minehata, K; Motegi, Y; Uno, S | 1 |
| Gore, S; Gorshein, E; Weber, UM | 1 |
| Almeida, A; Beach, CL; Fenaux, P; Giagounidis, A; Haferlach, T; List, AF; MacBeth, KJ; Mavrommatis, K; Platzbecker, U; Santini, V; Wu, C; Zhong, J | 1 |
| Karsan, A; Martinez-Høyer, S | 1 |
| Avet-Loiseau, H; Bahlis, NJ; Benboubker, L; Casneuf, T; Chari, A; Cochrane, T; Cook, G; Dimopoulos, MA; Iida, S; Joy Ho, P; Kaufman, JL; Kim, JS; Kim, K; Kobos, R; Krevvata, M; Leiba, M; Magen, H; Miles Prince, H; Moreau, P; Morton, J; O'Rourke, L; Oriol, A; San-Miguel, J; Sutherland, HJ; Takezako, N; Trivedi, S; Ukropec, J; Usmani, SZ; White, D | 1 |
| Avilés, A; Candelaria, M; Fabian-Morales, E; Gutierrez, O; Palacios-Campos, A | 1 |
| Döhner, K; Gabdoulline, R; Ganser, A; Ganster, C; Germing, U; Göhring, G; Gutermuth, A; Haase, D; Haferlach, C; Haferlach, T; Heuser, M; Kandziora, C; Klement, P; Klesse, S; Kobbe, G; Koenecke, C; Kröger, N; Krönke, J; Kubasch, AS; Meggendorfer, M; Mies, A; Panagiota, V; Platzbecker, U; Schiller, J; Schlegelberger, B; Schroeder, T; Shahswar, R; Shirneshan, K; Sperr, WR; Thiede, C; Thol, F; Valent, P | 1 |
| Bewersdorf, JP; Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Wang, R; Wang, X; Zeidan, AM; Zhang, C | 1 |
| Bug, G; Büsche, G; Fey, S; Germing, U; Giagounidis, A; Götze, KS; Haase, D; Haferlach, T; Hecht, A; Hofmann, WK; Jann, JC; Letsch, A; Lübbert, M; Metzgeroth, G; Meyer, JA; Müller, N; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Reinwald, M; Schafhausen, P; Schlenk, RF; Schuler, E; Sockel, K; Thol, F | 1 |
| Al Ali, N; Basiorka, AA; Fenaux, P; Fontenay, M; Komrokji, R; Kosmider, O; Lancet, JE; List, AF; McGraw, KL; McLemore, AF; Padron, E; Sallman, DA; Wang, C | 1 |
| Azevedo, RS; Bassolli, L; Belli, C; Buccheri, V; Castelli, JB; Enrico, A; Ferri, L; Junior, W; Magalhaes, SM; Pereira, T; Perusini, MA; Pinheiro, RF; Rocha, V; Schuster, S; Traina, F; Velloso, E | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Bacher, U; Braulke, F; Brümmendorf, TH; Bug, G; Büsche, G; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haas, R; Haase, D; Hofmann, WK; Letsch, A; Lübbert, M; Nolte, F; Platzbecker, U; Schafhausen, P; Schanz, J; Schlenk, RF; Schuler, E; Schulz, X; Shirneshan, K; Trümper, L | 1 |
| Bug, G; Fabarius, A; Fey, S; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haase, D; Haferlach, C; Hofmann, WK; Jann, JC; Letsch, A; Lübbert, M; Mossner, M; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Palme, I; Platzbecker, U; Pressler, J; Schlenk, R; Xanthopoulos, C | 1 |
| Bladé, JS; Boudin, L; de Jauréguiberry, JP; Patient, M; Roméo, E | 1 |
| Cortelezzi, A; Fattizzo, B; Ferla, V; Fracchiolla, NS; Freyrie, A; Iurlo, A; Reda, G | 1 |
| List, A; Sallman, D; Talati, C | 1 |
| Becht, E; Boeva, V; Cagnard, N; Chapuis, N; Chesnais, V; Chevret, S; Dumont, F; Fenaux, P; Fontenay, M; Fridman, WH; Kerdivel, G; Kosmider, O; Rousseau, A; Toma, A | 1 |
| Béné, MC; Cartron, G; Commes-Maerten, T; Delaunay, J; Eveillard, M; Flet, L; Gagez, AL; Godmer, P; Godon, C; Le Bris, Y; Lodé, L; Loirat, M; Luycx, O; Ménard, A; Pellat-Deceunynck, C; Peterlin, P; Richebourg, S; Soussi, T; Theisen, O; Villemagne, B | 1 |
| Almeida, A; Beach, CL; Castaneda, C; Fenaux, P; Garcia-Manero, G; Goldberg, SL; Gröpper, S; Jonasova, A; Santini, V; Vey, N; Zhong, J | 1 |
| Hellström-Lindberg, E; Jansson, M; Saft, L; Scharenberg, C | 1 |
| Shallis, RM; Zeidan, AM | 1 |
| Almeida, A; Altincatal, A; Beach, CL; Buckstein, R; Fenaux, P; Giagounidis, A; Guo, S; Platzbecker, U; Santini, V; Wu, C | 1 |
| Ebert, BL; Fenaux, P; List, A | 1 |
| Arcioni, F; Covezzoli, A; Cundari, S; Di Battista, V; Mecucci, C; Roncadori, A; Tura, S | 1 |
| Chaudhry, QUN; Iftikhar, R; Khan, MA; Mahmood, SK; Satti, TM; Shahbaz, N | 1 |
| Fenaux, P; Giagounidis, A; Göhring, G; Li, JS; List, AF; Mittelman, M; Schlegelberger, B; Sekeres, MA; Selleslag, D; Sugrue, MM; Swern, AS | 1 |
| Al-Kali, A; Alkharabsheh, OA; Alkhateeb, HB; Begna, KH; Elliott, MA; Gangat, N; Hogan, WJ; Litzow, MR; Patnaik, MS; Saadeh, SS; Zblewski, DL | 1 |
| Burgos, S; Fuente, L; Garcia-Manero, G; Jabbour, EJ; Kanagal-Shamanna, R; Mela-Osorio, MJ; Montalban-Bravo, G; Soltysiak, KA | 1 |
| Gonzalez, S; Gonzalez-Garcia, E; Gonzalez-Rodriguez, AP; López-Soto, A; Lorenzo-Herrero, S; Payer, AR; Sordo-Bahamonde, C; Villa-Álvarez, M; Villa-Álvarez, MC | 1 |
| Akyüz, N; Asemissen, AM; Binder, M; Bonzanni, N; Fuchs, P; Germing, U; Hofmann, WK; Jann, JC; Mährle, T; Nolte, F; Nowak, D; Simnica, D | 1 |
| Chisti, MM; Fennell, T; Sanders, DS | 1 |
| Alati, C; Alimena, G; Aloe Spiriti, MA; Balleari, E; Breccia, M; Cortelezzi, A; D'Errigo, MG; Finelli, C; Galimberti, S; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Palumbo, G; Poloni, A; Rodà, F; Sanpaolo, G; Specchia, G; Volpe, A | 1 |
| Ades, L; Bally, C; Chesnais, V; Dreyfus, F; Fenaux, P; Fontenay, M; Kaltenbach, S; Kosmider, O; Leschi, C; Park, S; Rouquette, A; Santini, V; Sardnal, V; Toma, A | 1 |
| Alvarez, S; Arenillas, L; Calasanz, MJ; Cervera, J; Cigudosa, JC; Costa, D; Del Rey, M; Diez-Campelo, M; Florensa, L; González-Martínez, T; Hernández, JM; Ibáñez, M; Jerez, A; Larráyoz, MJ; Lumbreras, E; Maciejewski, J; Mallo, M; Marugán, I; Nomdedeu, M; Pedro, C; Solé, F; Such, E | 1 |
| Scott, LJ; Syed, YY | 1 |
| Gironella, M; López-Andreoni, L; Mallo, M; Martínez-Morgado, N; Ortega, M; Sánchez-Morata, C; Solé, F; Valcárcel, D; Vallespí, T | 1 |
| Baer, MR; Davidoff, AJ; Gore, SD; Hendrick, F; Mahmoud, D; McNally, DL; Zeidan, AM | 1 |
| Arceci, RJ; Atsidaftos, E; Blanc, L; Bodine, DM; Ebert, BL; Ellis, SR; Farrar, JE; Gazda, HT; Landowski, M; Lipton, JM; Liu, JM; Markello, TC; Muir, E; Narla, A; Singh, SA; Vlachos, A | 1 |
| Cuzzola, M; Gentile, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
| Fenaux, P; Germing, U; Giagounidis, A; List, A; MacBeth, KJ; Mufti, GJ | 1 |
| Bennett, JM; Fu, T; Giagounidis, A; Knight, RD; List, AF; Nimer, SD; Sekeres, MA; Shammo, JM; Skikne, B | 1 |
| Ardanaz, MT; Arrizabalaga, B; Azaceta, G; Bargay, J; Cabrero, M; Calabuig, M; Cedena, T; Cerveró, C; Collado, R; del Cañizo, C; Díez-Campelo, M; García, M; Luño, E; Morell, MJ; Muñoz, JA; Nomdedeu, B; Pedro, C; Rodríguez, MJ; Rojas, SM; Simiele, A; Xicoy, B | 1 |
| Abe, T; Arihara, Y; Fujii, S; Fujita, M; Hirako, T; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Miura, S; Nagashima, K; Sakurai, T; Yamada, M; Yoshida, M | 1 |
| Kuendgen, A | 1 |
| Ebert, BL; Komrokji, RS; List, AF; Padron, E | 1 |
| Besa, EC; Gaballa, MR | 1 |
| Arilla, MJ; Arrizabalaga, B; Azaceta, G; Bailén, A; Bargay, J; Brunet, S; Cerveró, C; de Paz, R; Del Cañizo, C; Diez-Campelo, M; Falantes, J; García-Pintos, M; Lorenzo, I; Luño, E; Marco-Betes, V; Nomdedeu, B; Osorio, S; Ramos, F; Sánchez-García, J; Sanz, GF; Serrano-López, J; Such, E; Tormo, M; Valcárcel, D; Xicoy, B | 1 |
| Benettaib, B; Beyne-Rauzy, O; Bowen, D; del Cañizo, C; Fenaux, P; Fu, T; Ganser, A; Giagounidis, A; Göhring, G; Guerci-Bresler, A; Hellström-Lindberg, E; Lübbert, M; Mittelman, M; Mufti, GJ; Muus, P; Nilsson, L; Platzbecker, U; Quesnel, B; Sanz, G; Schlegelberger, B; Selleslag, D; te Boekhorst, P | 1 |
| Burger, J; Faderl, S; Ferrajoli, A; Jain, N; Keating, MJ; O'Brien, SM; Strati, P; Tambaro, FP; Wierda, WG | 1 |
| Ise, M; Kumagai, K; Sakai, C; Tsujimura, H | 1 |
| Alfinito, F; Avilia, S; Catalano, L; Cerchione, C; Cerciello, G; Pane, F; Picardi, M; Pisano, I; Risitano, AM | 1 |
| Bennett, JM; Dreyfus, F; Fenaux, P; Greenberg, PL; Li, JS; List, AF; Sanz, GF; Sekeres, MA; Sugrue, MM; Swern, AS | 1 |
| Bokorova, R; Brezinova, J; Cermak, J; Cervinek, L; Fuchs, O; Hajkova, H; Jonasova, A; Kostecka, A; Michalova, K; Mikulenkova, D; Neuwirtova, R; Polak, J; Siskova, M; Sponerova, D; Vostry, M | 1 |
| Belickova, M; Cermak, J; Hrustincova, A; Jonasova, A; Klema, J; Krejcik, Z; Merkerova, MD; Michalova, K; Stara, E; Zemanova, Z | 1 |
| Bornhäuser, M; Ehninger, G; Kramer, M; Mohr, B; Oelschlaegel, U; Parmentier, S; Platzbecker, U; Sockel, K; Thiede, C; van de Loosdrecht, AA; Westers, TM | 1 |
| Sun, C; Wiestner, A | 1 |
| Bellotti, D; Boiocchi, L; Borlenghi, E; Cerqui, E; Imberti, L; Lamorgese, C; Pagani, C; Pelizzari, A; Rossi, G; Schieppati, F; Sottini, A | 1 |
| Beličková, M; Čermák, J; Dostálová Merkerová, M; Hruštincová, A; Jonášová, A; Kléma, J; Krejčík, Z; Michalová, K; Zemanová, Z | 1 |
| Breccia, M; Carmosino, I; Finsinger, P; Latagliata, R; Mancini, M; Montagna, C; Oliva, E; Roberto, A; Romano, A; Volpicelli, P; Vozella, F | 1 |
| Barančik, M; Breier, A; Gibalová, L; Jonášová, A; Messingerová, L; Poleková, L; Šereš, M; Sulová, Z | 1 |
| Bieniaszewska, M; Butrym, A; Kumiega, B; Lech-Maranda, E; Madry, K; Mazur, G; Mital, A; Patkowska, E; Rybka, J; Torosian, T; Warzocha, K; Wichary, R | 1 |
| Giagounidis, A | 1 |
| Bazargan, A; Giv, MJ; Yoosuff, A | 1 |
| Al, MJ; Armstrong, N; Blommestein, HM; Deshpande, S; Kleijnen, J; Noake, C; Riemsma, R; Ryder, S; Severens, JL; Worthy, G | 1 |
| Alati, C; Aloe Spiriti, MA; Balleari, E; Cortelezzi, A; D'Errigo, MG; Germing, U; Kündgen, A; Latagliata, R; Lauseker, M; Oliva, EN; Palumbo, GA; Poloni, A; Ricco, A; Ronco, F; Sanpaolo, G; Santacaterina, I; Volpe, A | 1 |
| Aschauer, G; Burgstaller, S; Fiegl, M; Fridrik, M; Girschikofsky, M; Greil, R; Keil, F; Linkesch, W; Nösslinger, T; Petzer, A; Stauder, R | 1 |
| Al Ali, NH; Komrokji, RS; Lancet, J; List, A; Padron, E; Zeidan, AM | 1 |
| Banos, A; Benramdane, R; Beyne-Rauzy, O; Bordessoule, D; Bouabdallah, K; Caillot, D; Chevret, S; Cheze, S; Chouffi, B; Cony-Makhoul, P; De Renzis, B; Delaunay, J; Dreyfus, F; Fenaux, P; Fontenay, M; Gardin, C; Gruson, B; Guerci-Bresler, A; Guilhot, F; Gyan, E; Isnard, F; Kosmider, O; Laribi, K; Legros, L; Lejeune, J; Maloum, K; Nimuboma, S; Petit, R; Preudhomme, C; Renneville, A; Rose, C; Salanoubat, C; Sanhes, L; Sardnal, V; Slama, B; Soussain, C; Stamatoullas, A; Taksin, AL; Tertian, G; Toma, A; Wattel, E; Wickenhauser, S | 1 |
| Komrokji, RS; List, AF | 4 |
| Beyne-Rauzy, O; Chesnais, V; Chevret, S; Delaunay, J; Dreyfus, F; Dumont, F; Fenaux, P; Fontenay, M; Kosmider, O; Lambert, J; Lejeune, J; Passet, M; Preudhomme, C; Raimbault, A; Renneville, A; Rose, C; Solary, E; Stamatoullas, A; Toma, A | 1 |
| Bacher, U; Braulke, F; Bug, G; Büsche, G; Ganser, A; Gattermann, N; Germing, U; Giagounidis, A; Götze, K; Haas, R; Haase, D; Letsch, A; Lübbert, M; Nolte, F; Platzbecker, U; Schafhausen, P; Schlenk, RF; Schuler, E; Shirneshan, K; Wulfert, M | 1 |
| Beličková, M; Bělohlávková, P; Čermák, J; Černá, O; Červinek, L; Hochová, I; Janoušová, E; Jonášová, A; Kačmářová, K; Rohoň, P; Šišková, M | 1 |
| Braulke, F; Bug, G; Büsche, G; Fey, S; Ganser, A; Germing, U; Giagounidis, A; Götze, K; Haase, D; Haferlach, T; Hofmann, WK; Jann, JC; Lauinger-Lörsch, E; Letsch, A; Lübbert, M; Metzgeroth, G; Mossner, M; Müller, N; Nolte, F; Nowak, D; Nowak, V; Obländer, J; Platzbecker, U; Pressler, J; Schafhausen, P; Schlenk, RF; Schuler, E; Shirneshan, K; Weiß, C | 1 |
| Bostrom, B; Vundamati, D | 1 |
| Balaian, E; Bornhäuser, M; Ehninger, G; Germing, U; Haase, D; Mohr, B; Oelschlaegel, U; Ordemann, R; Platzbecker, U; Schönefeldt, C; Schuster, C; Tuve, S; von Bonin, M; Wermke, M | 1 |
| Deng, ZQ; He, PF; Lian, XY; Lin, J; Qian, J; Wen, XM; Xu, ZJ; Yang, L; Yao, DM; Zhang, ZH | 1 |
| Boultwood, J; Dimitriou, M; Douagi, I; Giai, V; Grandien, A; Hellström-Lindberg, E; Jacobsen, SE; Jädersten, M; Jansson, M; Karimi, M; LeBlanc, K; Neuberg, DS; Pellagatti, A; Saft, L; Scharenberg, C; Woll, PS | 1 |
| Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H | 1 |
| Frederiksen, H; Marcher, CW; Mortensen, TB; Preiss, B | 1 |
| Al Ali, N; Cluzeau, T; Fenaux, P; Gore, SD; Komrokji, R; Park, S; Prebet, T; Sekeres, MA; Sugrue, MM; Toma, A; Vey, N | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Cazzola, M | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Burcheri, S; Chaury, MP; Delaunay, J; Dreyfus, F; Fenaux, P; Gardin, C; Hoarau, N; Laurent, G; Legros, L; Mbida, RM; Prebet, T; Ravoet, C; Stamatoullas, A; Vey, N | 1 |
| Palumbo, A; Rajkumar, SV | 1 |
| Wiernik, PH | 1 |
| Bacher, U; Haferlach, C; List, A; Maciejewski, JP; Tiu, R | 1 |
| Cantalapiedra, A; Conde, J; Garcia Frade, LJ; Peñarrubia, MJ; Silvestre, LA | 1 |
| Ehninger, G; Mohr, B; Oelschlaegel, U; Platzbecker, U; Stewart, MM; Thiede, C | 1 |
| Hussein, K; Tefferi, A | 1 |
| Bahlis, NJ; Bruyere, H; Chang, H; Chen, C; Fu, T; Horsman, DE; Mansoor, A; Masih-Khan, E; Reece, D; Roland, B; Song, KW; Stewart, DA; Trieu, Y | 1 |
| Basile, FG | 1 |
| Stone, RM | 1 |
| Byrd, J; Chen, X; Dewald, G; Djeu, JY; Epling-Burnette, PK; Lawrence, N; List, A; Liu, Q; Maciejewski, J; Pireddu, R; Rocha, K; Sokol, L; Wei, S; Williams, A | 1 |
| Chang, C; He, Q; Li, X; Wu, L; Xu, F; Zhang, Q; Zhang, Z | 1 |
| Asch, J; Ford, CD; Konopa, K; Petersen, FB | 1 |
| Das, B; Goel, S; Heuck, C; Kotla, V; Nischal, S; Verma, A; Vivek, K | 1 |
| Abruzzo, L; Borthakur, G; Bueso-Ramos, C; Faderl, S; Garcia-Manero, G; Issa, JP; Kantarjian, H; O'Brien, S; Pierce, S; Ravandi, F; Shan, J | 1 |
| Harada, H; Kimura, A; Matsuda, A; Ozawa, K; Suzuki, K; Suzuki, T; Takatoku, M; Takeshita, K; Taniwaki, M; Tohyama, K; Tsudo, M; Watanabe, M; Yanagita, S; Yoshida, Y | 1 |
| Blum, S; Cavassini, M; Fayet, A; Jotterand, M; Lambert, JF; Schapira, M | 1 |
| Galanopoulos, A; Giannikou, K; Hatzimichael, E; Kartasis, Z; Klaus, M; Kokoris, S; Korkolopoulou, P; Liapi, D; Papadaki, HA; Pappa, V; Parcharidou, A; Pontikoglou, C; Psyllaki, M; Sambani, C; Symeonidis, A; Ximeri, M | 1 |
| List, A | 1 |
| Boultwood, J; Göhring, G; Hellström-Lindberg, E; Jädersten, M; Pellagatti, A; Porwit, A; Saft, L; Schlegelberger, B; Wainscoat, JS | 1 |
| Aul, C; Büsche, G; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Kreipe, HH; Schlegelberger, B; Zimmermann, M | 1 |
| Aprile, L; Bocchia, M; Chitarrelli, I; Defina, M; Fabbri, A; Gozzetti, A; Lauria, F; Rondoni, M | 1 |
| Bonkowski, J; Kolesar, JM; Vermeulen, LC | 1 |
| Bazargan, A; Tam, CS | 1 |
| Sekeres, MA | 1 |
| Bilgrami, SA; Block, AW; Chanan-Khan, AA; Czuczman, MS; Hernandez-Ilizaliturri, F; Lawrence, D; Lawrence, W; Lee, K; Miller, A; Miller, KC; Sher, T; Sood, R; Whitworth, A; Wood, MT | 1 |
| Chen, W; Fan, L; Li, W; Liu, L; Liu, X; Xiong, B; Zou, P | 1 |
| Kishimoto, M; Kondo, T; Matsuoka, A; Nakahara, T; Tasaka, T; Tochigi, A; Tohyama, K; Tohyama, Y; Tsujioka, T | 1 |
| Kulharya, A; Shah, R; Ustun, C; Yuan, J | 1 |
| Jädersten, M | 1 |
| Belkaid, M; Campo, E; Carrió, A; Costa, D; Coutinho, R; Muñoz, C; Nomdedeu, B; Vidal, A | 1 |
| Clima, J; Galili, N; Quddus, F; Raza, A; Sajjad, G; Seedham, H | 1 |
| Komrokji, RS; Lancet, JE; List, AF | 1 |
| Sirulnik, LA; Stone, RM | 1 |
| Alimena, G; Aloe Spiriti, MA; Breccia, M; Cortelezzi, A; Cuzzola, M; D'Errigo, MG; Finelli, C; Galimberti, S; Ghio, R; Iacopino, P; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Poloni, A; Ronco, F; Specchia, G | 1 |
| Dumas, PY; Milpied, N; Pigneux, A; Tabrizi, R | 1 |
| Christoulas, D; Dimopoulos, MA; Efstathiou, E; Gavriatopoulou, M; Gkotzamanidou, M; Iakovaki, M; Kastritis, E; Matsouka, C; Migkou, M; Mparmparoussi, D; Roussou, M; Terpos, E | 1 |
| Anderson, K; Astrand-Grundström, I; Buza-Vidas, N; Dhanda, RS; Ferry, H; Göhring, G; Hast, R; Hellström-Lindberg, E; Horvat, A; Jacobsen, SE; Johansson, B; List, A; Mead, AJ; Mizukami, T; Nilsson, L; Rydén, T; Schlegelberger, B; Strömbeck, B; Tehranchi, R; Vyas, P; Woll, PS | 1 |
| Hofmann, WK; Nolte, F | 1 |
| Azaceta, G; Bonafonte, E; Calasanz, MJ; Dourdil, V; Izquierdo, I; Palomera, L | 1 |
| Chmarzyńska, E; Dwilewicz-Trojaczek, J; Jędrzejczak, WW; Koperski, Ł; Pastwińska, A; Paszkowska-Kowalewska, M; Ziarkiewicz, M; Ziarkiewicz-Wróblewska, B | 1 |
| Carter, T; Chopra, R; Heise, C; Schafer, P | 1 |
| Büsche, G; Fenaux, P; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Hofmann, W; Kreipe, HH; Schlegelberger, B | 1 |
| Alimena, G; Barzotti, R; Breccia, M; Cannella, L; Ferretti, A; Latagliata, R; Loglisci, G; Nanni, M; Oliva, EN; Santopietro, M | 1 |
| Jädersten, M; Karsan, A | 1 |
| Bauer, F; Dasanu, CA; Davis, LK; Reale, MA; Schwartz, RA; Silver, JS | 1 |
| Komrokji, R; List, AF; Padron, E | 2 |
| Alimena, G; Breccia, M; Cannella, L; Latagliata, R; Loglisci, G; Oliva, EN; Salaroli, A; Santopietro, M | 1 |
| Adès, L; Fenaux, P | 2 |
| Sanchez, JF | 1 |
| Komrokji, RS; List, AF; Sekeres, MA | 1 |
| Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A | 1 |
| Advani, A; Appelbaum, FR; Gundacker, H; Lancet, J; Liesveld, J; List, AF; Mulford, D; Norwood, T; Petersdorf, S; Sekeres, MA; Willman, CL | 1 |
| Alimena, G; Breccia, M; Cannella, L; Carmosino, I; Cuzzola, M; Ferretti, A; Girmenia, C; Latagliata, R; Loglisci, G; Oliva, EN; Santopietro, M; Volpicelli, P; Vozella, F | 1 |
| Elloumi, M; Fenaux, P; Hadiji Mseddi, S; Jedidi, I; Kallel, F; Kassar, O; Sennana, H | 1 |
| Arumainathan, A; Kalakonda, N; Pettitt, AR | 1 |
| Adès, L; Banos, A; Beyne-Rauzy, O; Blanc, M; de Botton, S; Delaunay, J; Delmer, A; Dreyfus, F; Eclache, V; Fenaux, P; Guerci, A; Kelaidi, C; Lamy, T; Le Bras, F; Rea, D; Schmidt, A; Sebert, M; Turlure, P; Vey, N; Visanica, S | 1 |
| Aul, C; Beyne-Rauzy, O; Bowen, D; Cazzola, M; Del Cañizo, C; Fenaux, P; Francis, J; Fu, T; Ganser, A; Giagounidis, A; Guerci-Bresler, A; Hellström-Lindberg, E; Knight, R; Lübbert, M; Mittelman, M; Mufti, G; Muus, P; Nilsson, L; Platzbecker, U; Quesnel, B; Sanz, G; Schlegelberger, B; Selleslag, D; Te Boekhorst, P | 1 |
| Sekeres, MA; Tiu, RV | 1 |
| Aguilar, JL; Baumann, T; Calvo, X; Cervantes, F; Colomer, D; Costa, D; Díaz-Beyá, M; Esteve, J; Maffioli, M; Martínez-Trillos, A; Nomdedeu, B; Nomdedeu, M; Rozman, M | 1 |
| Büsche, G; Giagounidis, A; Göhring, G; Hellström-Lindberg, E; Hofmann, W; Kreipe, H; Lange, K; Morgan, M; Nielsen, KV; Roy, L; Schlegelberger, B | 1 |
| Katayama, Y | 1 |
| Basinko, A; De Braekeleer, E; De Braekeleer, M; Douet-Guilbert, N; Le Bris, MJ; Morel, F | 1 |
| Cairoli, A; Voutsadakis, IA | 1 |
| Aul, C; Büsche, G; Germing, U; Giagounidis, AA; Göhring, G; Haase, S; Kulasekararaj, A; Mufti, GJ; Petersen, P; Platzbecker, U; Radkowski, R | 1 |
| Adès, L; Banos, A; Blanc, M; Bouscary, D; Bresler, AG; Cabrol, MP; Chevret, S; Delaunay, J; Delmer, A; Dreyfus, F; Eclache, V; Fenaux, P; Kelaidi, C; Lamy, T; Le Bras, F; Sebert, M; Turlure, P; Vey, N; Visanica, S; Wattel, E | 1 |
| Harada, H; Jinnai, I; Kimura, A; Matsuda, A; Ozawa, K; Suzuki, K; Suzuki, T; Takatoku, M; Taniwaki, M; Tohyama, K; Tsudo, M; Watanabe, M; Yanagita, S; Yoshida, Y | 1 |
| Himmelmann, A; Tchinda, J | 1 |
| Abkowitz, JL; Keel, SB; Kirn-Safran, CB; O'Leary, MN; Phelps, S; Sabo, KM | 1 |
| Banos, A; Baracco, F; Besson, C; Blanc, M; Cannas, G; Corm, S; Fenaux, P; Perrier, H; Prebet, T; Sibon, D; Slama, B; Vey, N; Wattel, E | 1 |
| Afable, M; Guinta, K; Jankowska, A; Jerez, A; List, AF; Maciejewski, J; Makishima, H; McGraw, KL; O'Keefe, CL; Sekeres, MA; Sugimoto, Y; Szpurka, H; Tiu, R; Traina, F; Visconte, V | 1 |
| Billingsley, D; Caceres, G; Chen, X; Clark, J; Djeu, J; Eksioglu, EA; Epling-Burnette, PK; Fortenbery, N; Komrokji, R; Lancet, J; List, A; Maciejewski, JP; McGraw, K; Sallman, D; Sekeres, M; Sokol, L; Wang, H; Wei, S; Zhang, L; Zhou, J | 1 |
| Boccia, R; Brown, GL; Galili, N; Garcia-Manero, G; Lyons, RM; Mesa, RA; Mulford, D; Raza, A; Sekeres, MA; Smith, SE; Steensma, DP | 1 |
| Matsuoka, A; Tohyama, K; Tohyama, Y; Tsujioka, T | 1 |
| Borthakur, G; Chen, Y; Cortes, J; Estrov, Z; Faderl, S; Kantarjian, H; Ravandi, F; Rey, K | 1 |
| Belickova, M; Caniga, M; Cechova, E; Cermak, J; Dostalova Merkerova, M; Jonasova, A; Krejcik, Z; Michalova, K; Neuwirtova, R; Vesela, J; Votavova, H; Zemanova, Z | 1 |
| Buckstein, R; Leitch, HA; Shamy, A; Storring, JM | 1 |
| Caceres, G; Deeg, HJ; Karsan, A; List, AF; Nevill, TJ; Platzbecker, U; Scott, BL; Sokol, L; Sung, S; Venner, CP; Woltosz, JW | 1 |
| Abouyahya, I; Alhan, C; Coenen, JL; de Kruijf, EJ; de Wolf, JT; Heyning, FH; Huls, GA; Imholz, AL; Kappers-Klunne, MC; Koedam, J; Koene, HR; Muus, P; Ossenkoppele, GJ; Planken, EV; Segeren, CM; te Boekhorst, PA; van de Loosdrecht, AA; van der Velden, AM; Vasmel, WL; Velders, GA; Veth, G; Westers, TM | 1 |
| Alimena, G; Aloe Spiriti, MA; Breccia, M; Cortelezzi, A; Cuzzola, M; Finelli, C; Galimberti, S; Ghio, R; Laganà, C; Latagliata, R; Morabito, F; Nobile, F; Oliva, EN; Palumbo, GA; Poloni, A; Ricco, A; Rigolino, C; Rodà, F; Sanpaolo, G; Volpe, A | 1 |
| Giagounidis, AA | 1 |
| Backstrom, J; Brandenburg, NA; Fenaux, P; Germing, U; Giagounidis, AA; Glasmacher, A; Hasford, J; Kuendgen, A; Lauseker, M; List, AF | 1 |
| Brandenburg, NA; Fenaux, P; Knight, R; Muus, P; Revicki, DA; Yu, R | 1 |
| Bornhäuser, M; Braulke, F; Bug, G; Ehninger, G; Germing, U; Giagounidis, A; Götze, K; Haase, D; Hofmann, WK; Kündgen, A; Naumann, R; Neesen, J; Platzbecker, U; Röllig, C; Schönefeldt, C; Shirneshan, K; Wermke, M | 1 |
| Abruzzo, L; Cortes, J; Kantarjian, H; Pierce, S; Takahashi, K; Verstovsek, S | 1 |
| Aul, C; Boultwood, J; Germing, U; Giagounidis, AA; Wainscoat, JS | 1 |
| Aul, C; Germing, U; Giagounidis, AA; Heinsch, M; Hildebrandt, B; Strupp, C | 1 |
| Harousseau, JL; Moreau, P | 1 |
| Aul, C; Germing, U; Giagounidis, AA | 1 |
| Galili, N; Raza, A | 1 |
| Li, CY; Mesa, RA; Steensma, DP; Tefferi, A | 1 |
| Bennett, J; Dewald, G; Feldman, E; Giagounidis, A; Greenberg, P; Knight, R; List, A; Patin, J; Powell, B; Raza, A; Reeder, C; Schmidt, M; Stone, R; Thomas, D; Wride, K; Zeldis, J | 1 |
| Aul, C; Giagounidis, AA; Göhring, G; Haase, S; Heinsch, M; Schlegelberger, B | 1 |
| Lancet, JE; List, AF; Moscinski, LC | 1 |
| Baker, AF; Bellamy, W; Green, S; List, AF | 1 |
| List, AF | 1 |
| Goss, TF; Hellström-Lindberg, E; Jädersten, M; Knight, R; List, AF; Schaefer, C; Szende, A; Totten, PJ | 1 |
| Kurtin, S; Sokol, L | 1 |
| Kale, V; List, A; Melchert, M | 1 |
| List, A; Melchert, M; Williams, C | 1 |
| Hanson, CA; Ketterling, RP; Lasho, TL; Mesa, RA; Pardanani, A; Tefferi, A | 1 |
| Bennett, JM; Curtin, PT; Deeg, HJ; Dewald, GW; Dreisbach, L; Feldman, EJ; Greenberg, PL; Klimek, VM; Knight, RD; List, AF; Raza, A; Reeves, JA; Schiffer, CA; Schmidt, M; Shammo, JM; Stone, RM; Thomas, D; Wride, K; Zeldis, JB | 1 |
| List, A; Ortega, J | 1 |
| Eclache, V; Fenaux, P; Kelaidi, C | 1 |
| Bargou, R; Cosgrove, D; Einsele, H; Knop, S; List, A | 1 |
| Bosco, J; Ebert, BL; Galili, N; Golub, TR; Ladd-Acosta, C; Mak, R; Pretz, J; Raza, A; Stone, R; Tamayo, P; Tanguturi, S | 1 |
43 review(s) available for lenalidomide and Chromosome Deletion
| Article | Year |
|---|---|
Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Tumor Suppressor Protein p53 | 2020 |
Mechanisms of lenalidomide sensitivity and resistance.
Topics: Adaptor Proteins, Signal Transducing; Anemia, Macrocytic; Angiogenesis Inhibitors; Antineoplastic Agents; Autophagy; Cell Differentiation; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytokines; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Ikaros Transcription Factor; Immunologic Factors; Lenalidomide; Megakaryocytes; Multiple Myeloma; Neoplasm Proteins; Neovascularization, Pathologic; Phosphoprotein Phosphatases; Ubiquitin-Protein Ligases | 2020 |
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2017 |
A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.
Topics: Animals; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Management; Disease Progression; Drug Development; Genetic Heterogeneity; Genetic Predisposition to Disease; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Prognosis; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.
Topics: Anemia; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Topics: Angiogenesis Inhibitors; Apoptosis; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Disease Progression; Erythropoiesis; Gene Dosage; Genes, Tumor Suppressor; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Survival Analysis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2014 |
Deletion 5q MDS: molecular and therapeutic implications.
Topics: Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoiesis; Haploinsufficiency; Humans; Lenalidomide; Megakaryocytes; MicroRNAs; Myelodysplastic Syndromes; Phenotype; Ribosomal Proteins; Thalidomide; Tumor Suppressor Protein p53 | 2013 |
Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Gene Expression; Haploinsufficiency; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; MicroRNAs; Myelodysplastic Syndromes; Practice Guidelines as Topic; Ribosomal Proteins; Thalidomide; Tumor Suppressor Protein p53 | 2014 |
Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Humans; Integrin alpha4; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Precision Medicine; Prognosis; Protein Kinase Inhibitors; Smith-Magenis Syndrome; Thalidomide; ZAP-70 Protein-Tyrosine Kinase | 2015 |
Where Does Lenalidomide Fit in Non-del(5q) MDS?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 5; Combined Modality Therapy; Humans; Immunologic Factors; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Patient Selection; Thalidomide; Treatment Outcome | 2015 |
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.
Topics: Angiogenesis Inhibitors; Chromosome Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Risk; Thalidomide; Treatment Outcome | 2016 |
Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
Topics: Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2016 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic | 2017 |
Treatment of newly diagnosed myeloma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Clinical Trials as Topic; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Middle Aged; Multiple Myeloma; Myeloma Proteins; Prognosis; Pyrazines; Risk; Thalidomide; Translocation, Genetic; Transplantation Conditioning | 2009 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
Mechanism of action of lenalidomide in hematological malignancies.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Hematologic Neoplasms; Humans; Immunomodulation; Lenalidomide; Models, Biological; Neovascularization, Pathologic; Signal Transduction; Thalidomide | 2009 |
Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Clinical Trials as Topic; Disease Progression; Humans; Immunosuppression Therapy; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Medical Oncology; Myelodysplastic Syndromes; Risk; Thalidomide; Treatment Outcome | 2009 |
The clinical utility of lenalidomide in multiple myeloma and myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Costs; Drug Interactions; Humans; Lenalidomide; Multiple Myeloma; Myelodysplastic Syndromes; Thalidomide | 2010 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
Topics: Aged; Anemia; Animals; Apoptosis; Blood Transfusion; Bone Marrow; cdc25 Phosphatases; Cell Nucleus; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Combined Modality Therapy; Erythropoiesis; Forecasting; G2 Phase; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Rats; Receptors, Erythropoietin; Thalidomide | 2010 |
Lenalidomide in myelodysplastic syndromes: an erythropoiesis-stimulating agent or more?
Topics: Anemia; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Clone Cells; Combined Modality Therapy; Disease Progression; Erythropoiesis; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Risk; Survival Analysis; Thalidomide | 2010 |
[Current treatment options for myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Iron Overload; Lenalidomide; Leukemia, Myeloid, Acute; Long-Term Care; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Thalidomide | 2010 |
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoiesis; Genes; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2010 |
Biology and treatment of the 5q- syndrome.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Gene Deletion; Humans; Lenalidomide; Thalidomide | 2011 |
Treatment of myelodysplastic syndromes in elderly patients.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Management; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Contraindications; Hematinics; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunomodulation; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Thalidomide | 2011 |
Management of lower-risk myelodysplastic syndromes: the art and evidence.
Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Female; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Thalidomide | 2011 |
[Molecular mechanisms of lenalidomide for the treatment of myelodysplastic syndromes].
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Genes, p53; Haploidy; Humans; Lenalidomide; MicroRNAs; Molecular Targeted Therapy; Myelodysplastic Syndromes; Ribosomal Proteins; Thalidomide | 2011 |
Role of lenalidomide in the treatment of myelodysplastic syndromes.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2011 |
A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Haploinsufficiency; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2012 |
Immunomodulating drugs in myelodysplastic syndromes.
Topics: Chromosome Deletion; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Risk Factors; Thalidomide | 2011 |
Lenalidomide for treatment of myelodysplastic syndromes.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2012 |
Approach to new therapeutics: investigation by the use of MDS-derived cell lines.
Topics: Animals; Cell Line; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; DNA Modification Methylases; Enzyme Inhibitors; Gene Expression Profiling; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide | 2012 |
The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Immunologic Factors; Karyotype; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Thalidomide | 2013 |
Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2012 |
Evolving role of stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Disease-Free Survival; Humans; Immunosuppressive Agents; Lenalidomide; Multiple Myeloma; Pyrazines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2005 |
Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Female; Hematopoiesis; Humans; Lenalidomide; Male; Myeloproliferative Disorders; Prognosis; Thalidomide | 2006 |
Immunomodulatory drugs in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Animals; Apoptosis; Blood Transfusion; Cell Lineage; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Cytokines; Drug Evaluation, Preclinical; Drugs, Investigational; Erythrocyte Transfusion; Erythropoiesis; Female; Hematopoietic Stem Cells; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; NF-kappa B; Pilot Projects; Thalidomide; Thrombocytopenia; Tumor Necrosis Factor-alpha | 2006 |
Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
Topics: Anemia; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Delivery Systems; Erythropoiesis; Erythropoietin; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide; Treatment Outcome | 2006 |
Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
Topics: Algorithms; Anemia; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Delivery Systems; Humans; Lenalidomide; Medical Oncology; Myelodysplastic Syndromes; Practice Guidelines as Topic; Risk Factors; Thalidomide | 2006 |
The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2007 |
Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Topics: Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2007 |
The role of lenalidomide in the management of myelodysplasia with del 5q.
Topics: Anemia, Refractory; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome | 2008 |
36 trial(s) available for lenalidomide and Chromosome Deletion
| Article | Year |
|---|---|
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Topics: Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Phase I trial of the combination of ibrutinib and lenalidomide of the treatment of patients with MDS who have failed standard therapy or who are unfit for or refuse standard therapy.
Topics: Adenine; Chromosome Deletion; Humans; Lenalidomide; Piperidines | 2022 |
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human; Cytogenetic Analysis; Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Recurrence; Survival Rate; Translocation, Genetic | 2020 |
Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA Methylation; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2021 |
Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antigens, CD34; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease-Free Survival; Female; Germany; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Leukemia, Myeloid; Leukocytes, Mononuclear; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Failure | 2017 |
Safety profile of lenalidomide in patients with lower-risk myelodysplastic syndromes without del(5q): results of a phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Diarrhea; Exanthema; Fatigue; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Risk Factors; Spasm | 2018 |
The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Double-Blind Method; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality of Life; Risk Factors; Surveys and Questionnaires | 2018 |
Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.
Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Immunologic Factors; Italy; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Prospective Studies; Registries; Remission Induction; Retrospective Studies; Thalidomide | 2018 |
Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Incidence; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk Factors; Venous Thrombosis | 2019 |
Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Bone Marrow; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; T-Lymphocyte Subsets; Tumor Microenvironment | 2019 |
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Quality of Life; Thalidomide; Treatment Outcome | 2013 |
Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Disease Progression; Drug Administration Schedule; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Risk; Survival Analysis; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
Topics: Adult; Aged; Anemia, Macrocytic; Biomarkers; Blood Proteins; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Myelodysplastic Syndromes; Reproducibility of Results; Sensitivity and Specificity; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Erythropoietin; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Prognosis; Prospective Studies; Risk Factors; Thalidomide | 2016 |
Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Clone Cells; DNA Mutational Analysis; Erythropoietin; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Treatment Outcome | 2016 |
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5).
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Prospective Studies; Thalidomide; Treatment Outcome | 2016 |
Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prevalence; Prospective Studies; Thalidomide; Tumor Suppressor Protein p53 | 2016 |
Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
Topics: Aged; Aged, 80 and over; Anemia, Macrocytic; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; T-Lymphocytes, Helper-Inducer; T-Lymphocytes, Regulatory; Thalidomide; Transforming Growth Factor beta | 2016 |
Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Disease-Free Survival; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Middle Aged; Multiple Myeloma; Salvage Therapy; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Asian People; Chromosome Deletion; Chromosomes, Human, Pair 5; Chronic Disease; Female; Humans; Japan; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Thalidomide; Treatment Outcome | 2009 |
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2010 |
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Cytogenetics; Disease-Free Survival; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prognosis; Recurrence; Risk; Thalidomide; Treatment Outcome | 2010 |
Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Ribosomal Proteins; Risk Factors; Thalidomide; Transcription, Genetic | 2010 |
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Thalidomide; Treatment Outcome | 2011 |
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Double-Blind Method; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide | 2011 |
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Drug Therapy, Combination; Female; Hematinics; Humans; Karyotype; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Thalidomide; Treatment Failure; Treatment Outcome | 2012 |
Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Female; Glutathione; Glutathione Transferase; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2012 |
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Thalidomide; Treatment Outcome | 2012 |
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study.
Topics: Aged; Anemia, Macrocytic; Apoptosis; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Forkhead Transcription Factors; Gene Dosage; Gene Expression Profiling; Gene Expression Regulation; Genetic Association Studies; Humans; Immunity, Innate; Lenalidomide; Male; MicroRNAs; Models, Genetic; Myelodysplastic Syndromes; Ribosomal Proteins; Signal Transduction; Thalidomide | 2013 |
Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Combined Modality Therapy; Cross-Over Studies; Double-Blind Method; Female; Health Status; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Placebos; Quality of Life; Risk; Severity of Illness Index; Thalidomide; Treatment Outcome | 2013 |
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2013 |
Chromosome 5q deletion is extremely rare in patients with myelofibrosis.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Primary Myelofibrosis; Retrospective Studies; Thalidomide | 2013 |
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Thalidomide | 2006 |
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Risk Factors; Thalidomide; Treatment Outcome | 2008 |
Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment.
Topics: Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Kidney Diseases; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2008 |
126 other study(ies) available for lenalidomide and Chromosome Deletion
| Article | Year |
|---|---|
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosome Mapping; Chromosomes, Human, Pair 5; Clone Cells; Erythroblasts; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Lenalidomide; Myelodysplastic Syndromes; Osteonectin; Thalidomide; Tumor Cells, Cultured | 2007 |
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS).
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Phosphoproteins; Prognosis; Retrospective Studies; RNA Splicing Factors; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2022 |
[MDS with deletion 5q - a distinct subtype of myelodysplastic syndromes].
Topics: Chromosome Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2022 |
Evolution of severe (transfusion-dependent) anaemia in myelodysplastic syndromes with 5q deletion is characterized by a macrophage-associated failure of the eythropoietic niche.
Topics: Anemia; Animals; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Macrophages; Mice; Myelodysplastic Syndromes; Thalidomide | 2022 |
Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Ferritins; Humans; Lenalidomide; Myelodysplastic Syndromes; Prospective Studies; Thalidomide; Treatment Outcome | 2022 |
Quantitative evaluation of treatment response to lenalidomide by applying fluorescence in situ hybridization for peripheral blood granulocytes in a patient with 5q- syndrome.
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cri-du-Chat Syndrome; Female; Granulocytes; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Trisomy | 2022 |
Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2022 |
Images from the Haematologica Atlas of Hematologic Cytology: myelodysplastic syndrome with isolated del(5q).
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes | 2022 |
Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; East Asian People; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Product Surveillance, Postmarketing; Thalidomide; Treatment Outcome | 2023 |
Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients.
Topics: Biomarkers, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Mutation; Myelodysplastic Syndromes; Prognosis; Survival Rate | 2021 |
Transitory response of a myelodysplastic syndrome with deletion of chromosome 5q to thalidomide. Report of one case.
Topics: Aged; Anemia, Macrocytic; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2020 |
Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Alleles; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Disease Progression; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Protein Phosphatase 2C; Retrospective Studies | 2021 |
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States.
Topics: Aged; Anemia, Refractory; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA; Humans; Lenalidomide; Medicare; Methyltransferases; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; United States | 2021 |
Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.
Topics: Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes | 2022 |
Age, Blasts, Performance Status and Lenalidomide Therapy Influence the Outcome of Myelodysplastic Syndrome With Isolated Del(5q): A Study of 58 South American Patients.
Topics: Age Factors; Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Analysis; Treatment Outcome | 2022 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Accurate quantification of chromosomal lesions via short tandem repeat analysis using minimal amounts of DNA.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Microsatellite Repeats; Middle Aged; Multiplex Polymerase Chain Reaction; Myelodysplastic Syndromes; Reproducibility of Results; Thalidomide; Uniparental Disomy | 2017 |
[Lenalidomide desensitization in a patient with 5q- syndrome].
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Desensitization, Immunologic; Drug Administration Schedule; Drug Eruptions; Female; Humans; Immunologic Factors; Lenalidomide | 2017 |
Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for.
Topics: Chromosome Deletion; Dendritic Cells; Humans; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neoplasms, Plasma Cell; Thalidomide; Treatment Outcome | 2017 |
Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling.
Topics: Aged; Aged, 80 and over; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2018 |
Emergence and evolution of
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Tumor Suppressor Protein p53 | 2018 |
Megakaryocytes harbour the del(5q) abnormality despite complete clinical and cytogenetic remission induced by lenalidomide treatment.
Topics: Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clonal Evolution; Cytogenetic Analysis; Hematologic Neoplasms; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Lenalidomide; Megakaryocyte-Erythroid Progenitor Cells; Megakaryocytes; Remission Induction; Thalidomide; Treatment Outcome | 2018 |
Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?
Topics: Abnormalities, Multiple; Chromosome Deletion; Chromosomes, Human, Pair 2; Humans; Lenalidomide; Myelodysplastic Syndromes | 2018 |
Lenalidomide Induced Toxic Epidermal Necrolysis and Del (5q): Co-occurrence of Rarities.
Topics: Anemia, Macrocytic; Calreticulin; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Primary Myelofibrosis; Stevens-Johnson Syndrome | 2018 |
The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Treatment Outcome | 2018 |
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; B-Lymphocytes; Bone Marrow; Chromosome Deletion; Cyclophosphamide; Dexamethasone; Disease Progression; Enhancer of Zeste Homolog 2 Protein; Humans; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Thrombocytopenia; Treatment Outcome | 2019 |
Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia.
Topics: Aged; Antibodies, Blocking; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cells, Cultured; Chromosome Deletion; Drug Synergism; Female; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Immunoglobulin-like Receptor B1; Male; Middle Aged | 2018 |
MDS with 5q deletion and rare
Topics: Anemia, Macrocytic; Biopsy; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Male; Mastocytosis; Middle Aged; Mutation; Myelodysplastic Syndromes | 2019 |
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q).
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Chromosome Deletion; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Peptide Hydrolases; Polymorphism, Genetic; Risk; Thalidomide; Ubiquitin-Protein Ligases | 2013 |
Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
Topics: Aged; Aged, 80 and over; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Thalidomide; Treatment Outcome | 2013 |
5q- syndrome and multiple myeloma diagnosed simultaneously and successful treated with lenalidomide.
Topics: Abnormal Karyotype; Aged; Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Female; Humans; Lenalidomide; Male; Medicare; Myelodysplastic Syndromes; Practice Patterns, Physicians'; Thalidomide; Treatment Outcome; United States | 2013 |
Diminutive somatic deletions in the 5q region lead to a phenotype atypical of classical 5q- syndrome.
Topics: Adolescent; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Genotype; Humans; Immunologic Factors; Lenalidomide; Phenotype; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Ribosomal Proteins; Thalidomide | 2013 |
Erythroid but not cytogenetic response in a case with 5q- syndrome: a delayed effect of lenalidomide or a consequence of deferasirox treatment?
Topics: Aged; Anemia, Macrocytic; Benzoates; Chromosome Deletion; Chromosomes, Human, Pair 5; Deferasirox; Erythroid Cells; Erythropoiesis; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; Triazoles | 2014 |
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
Topics: Aged; Chromosome Deletion; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Survival Analysis; Thalidomide | 2014 |
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Thalidomide; Time Factors | 2014 |
[A case in which chromosome 5q deletion syndrome resistant to lenalidomide therapy transformed to refractory anemia with excess blasts].
Topics: Aged, 80 and over; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Fatal Outcome; Humans; Lenalidomide; Male; Stevens-Johnson Syndrome; Thalidomide | 2013 |
The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide | 2014 |
Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Drug Evaluation; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Thalidomide; Treatment Outcome | 2014 |
Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 17; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Retrospective Studies; Rituximab; Smith-Magenis Syndrome; Thalidomide; Treatment Outcome | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Clone Cells; Dexamethasone; Fatal Outcome; Female; Gene Deletion; Genes, p53; Humans; Incidental Findings; Lenalidomide; Liver; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplasms, Multiple Primary; Osteolysis; Proteasome Inhibitors; Pyrazines; Recurrence; Thalidomide; Tumor Suppressor Protein p53; Uterine Neoplasms | 2014 |
Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA).
Topics: Adult; Aged; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Red-Cell Aplasia, Pure; Thalidomide | 2015 |
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survival Rate; Thalidomide | 2014 |
High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Topics: Adaptor Proteins, Signal Transducing; Anemia, Macrocytic; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 5; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; Leukocytes, Mononuclear; Myelodysplastic Syndromes; Peptide Hydrolases; Polymorphism, Single Nucleotide; RNA Splicing; RNA, Messenger; Signal Transduction; Thalidomide; Treatment Outcome; Ubiquitin-Protein Ligases | 2015 |
Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Topics: Aged; Anemia, Macrocytic; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 5; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Loci; Genome-Wide Association Study; Haploinsufficiency; Humans; Immunologic Factors; Lenalidomide; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Myelodysplastic Syndromes; Primary Cell Culture; RNA Splicing; Signal Transduction; Thalidomide | 2015 |
Myelodysplastic syndromes with a deletion 5q display a characteristic immunophenotypic profile suitable for diagnostics and response monitoring.
Topics: Antigens, CD; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Drug Monitoring; Female; Gene Expression; Humans; Immunologic Factors; Immunophenotyping; Lenalidomide; Lymphocytes; Male; Myelodysplastic Syndromes; Myeloid Cells; Thalidomide | 2015 |
Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Follow-Up Studies; Gene Expression; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
Aberrant expression of the microRNA cluster in 14q32 is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment.
Topics: Angiogenesis Inhibitors; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 5; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Lenalidomide; MicroRNAs; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Sequence Deletion; Thalidomide | 2015 |
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Topics: Aged; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Hematologic Diseases; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Pain; Remission Induction; Thalidomide; Time Factors; Treatment Outcome | 2015 |
Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Poland; Retrospective Studies; Thalidomide; Treatment Outcome | 2015 |
Use of Lenalidomide in 5q-Myelodysplastic Syndrome Provides Novel Treatment Prospects in Management of Pulmonary Sarcoidosis.
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Lung; Sarcoidosis, Pulmonary; Thalidomide; Tomography, X-Ray Computed | 2015 |
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Topics: Anemia, Macrocytic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Health Care Costs; Humans; Lenalidomide; Models, Economic; Myelodysplastic Syndromes; Quality-Adjusted Life Years; Technology Assessment, Biomedical; Thalidomide | 2016 |
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Follow-Up Studies; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Quality of Life; Thalidomide; Treatment Outcome | 2015 |
Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Angiogenesis Inhibitors; Austria; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Comorbidity; Disease Progression; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Standard of Care; Survival Analysis; Thalidomide; Treatment Outcome | 2015 |
Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Retreatment; Retrospective Studies; Thalidomide; Treatment Failure; Treatment Outcome | 2015 |
[Lenalidomide treatment in myelodysplastic syndrome with 5q deletion--Czech MDS group experience].
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2015 |
Prolonged Response in Patient With Multiply Relapsed B-cell Acute Lymphoblastic Leukemia and Monosomy-7 to Bortezomib, Lenalidomide, and Dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Child; Chromosome Deletion; Chromosomes, Human, Pair 7; Dexamethasone; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Thalidomide | 2016 |
Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.
Topics: Aged; Aged, 80 and over; Biomarkers; Chromosome Deletion; Chromosomes, Human, Pair 5; Computational Biology; Disease Progression; Female; Gene Expression; Gene Expression Profiling; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Mesenchymal Stem Cells; Middle Aged; Mutation; Myelodysplastic Syndromes; Prognosis; Stem Cell Niche; Thalidomide; Treatment Outcome | 2017 |
Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Resistance; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Purpura, Thrombocytopenic, Idiopathic; Remission Induction; Thalidomide | 2017 |
Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Survival Analysis; Thalidomide; Treatment Outcome; Young Adult | 2017 |
Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
Topics: Aged; Biomarkers, Tumor; Cell Transformation, Neoplastic; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid, Acute; Mutation; Myelodysplastic Syndromes; Prognosis | 2017 |
Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis.
Topics: Adult; Blood Platelets; Chemistry, Pharmaceutical; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Myelodysplastic Syndromes; Stem Cells; Syndrome; Thalidomide | 2008 |
Myelodysplastic syndromes with del(5q): indications and strategies for cytogenetic testing.
Topics: Algorithms; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Myelodysplastic Syndromes; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Prognosis; Spectral Karyotyping; Thalidomide | 2008 |
Hematologic and cytogenetic response to lenalidomide in de novo acute myeloid leukemia with chromosome 5q deletion.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Thalidomide; Treatment Outcome | 2009 |
The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells.
Topics: Aged; Antigens, CD34; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2009 |
Lenalidomide-induced durable hematological and cytogenetic remission in del(5q)-associated de novo acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Thalidomide; Treatment Outcome | 2009 |
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2009 |
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide.
Topics: Antineoplastic Agents; Apoptosis; cdc25 Phosphatases; Chromosome Deletion; Chromosomes, Human, Pair 5; G2 Phase; Humans; Lenalidomide; Myelodysplastic Syndromes; Protein Phosphatase 2; Thalidomide; U937 Cells | 2009 |
A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2009 |
CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Recurrence; Thalidomide | 2010 |
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
Topics: Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Monosomy; Myelodysplastic Syndromes; Prognosis; Risk; Survival Analysis; Thalidomide | 2009 |
Treatment of 5q-syndrome with lenalidomide in an HIV-positive patient under cART.
Topics: Anti-HIV Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; HIV Infections; Humans; Lenalidomide; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Thalidomide | 2010 |
Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow Cells; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Colony-Forming Units Assay; Cytokines; Female; Flow Cytometry; Hematopoiesis; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2010 |
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Topics: Aged; Antineoplastic Agents; Bone Marrow Cells; Chromosome Banding; Chromosome Deletion; Chromosomes, Human, Pair 5; Clone Cells; Disease Progression; Female; Gene Expression Profiling; Genetic Heterogeneity; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide; Tumor Suppressor Protein p53 | 2009 |
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Erythroid Cells; Female; Follow-Up Studies; Humans; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Thalidomide; Treatment Failure | 2010 |
New agents for the treatment of genetically high-risk chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Cyclophosphamide; Drug Therapy; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Medical Oncology; Risk; Rituximab; Thalidomide; Treatment Outcome; Vidarabine | 2010 |
Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
Topics: Aged; Angiogenesis Inhibitors; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 9; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Neoplasm, Residual; Remission Induction; Thalidomide | 2010 |
Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Division; Cell Proliferation; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytokinesis; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thalidomide; Tumor Cells, Cultured | 2010 |
Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Deletion; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 8; Clone Cells; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Karyotyping; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Polyploidy; Protease Inhibitors; Pyrazines; Thalidomide; Translocation, Genetic; Transplantation, Autologous | 2010 |
Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion.
Topics: Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2010 |
Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Clinical Trials as Topic; Cytogenetic Analysis; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Trisomy | 2010 |
Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 5; Erythroid Cells; Glutathione; Hemoglobins; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Remission Induction; Thalidomide; Treatment Outcome | 2010 |
Lenalidomide in myelodysplastic syndromes: where do we go from here?
Topics: Antineoplastic Agents; Chromosome Deletion; Humans; Lenalidomide; Myelodysplastic Syndromes; Stem Cell Transplantation; Thalidomide | 2008 |
Lenalidomide induces remission and mixed quantitative chimerism fluctuations in refractory and relapsed myeloid malignancy with del (5).
Topics: Adult; Antineoplastic Agents; Chimerism; Chromosome Deletion; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Remission Induction; Salvage Therapy; Sequence Deletion; Thalidomide | 2010 |
Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 17; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Persistent malignant stem cells in del(5q) myelodysplasia in remission.
Topics: ADP-ribosyl Cyclase 1; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Resistance; Female; Gene Expression; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neoplastic Stem Cells; Phenotype; Remission Induction; Thalidomide; Thy-1 Antigens | 2010 |
Response to lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 V617F mutation.
Topics: Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Mutation; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2010 |
Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Topics: Aged; Anemia, Macrocytic; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Thalidomide; Thrombocytosis | 2010 |
Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Remission Induction; Risk Factors; Survival Rate; Thalidomide | 2011 |
Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Topics: Acute Disease; Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid; Male; Myelodysplastic Syndromes; Spectral Karyotyping; Thalidomide | 2011 |
Clonal evolution in myelodysplastic syndromes with isolated del(5q): the importance of genetic monitoring.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Clone Cells; Humans; Lenalidomide; Myelodysplastic Syndromes; Remission Induction; Thalidomide | 2011 |
Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lenalidomide; Myeloproliferative Disorders; Neoplasms; Philadelphia Chromosome; Polycythemia Vera; Splenomegaly; Thalidomide | 2011 |
Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome.
Topics: Aged; Anemia, Macrocytic; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Erythroid Cells; Exanthema; Humans; Lenalidomide; Ribosomal Proteins; Thalidomide | 2011 |
[The 5q- syndrome].
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide | 2010 |
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 17; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Prognosis; Recurrence; Thalidomide; Translocation, Genetic | 2011 |
Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.
Topics: Aged; Anemia; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2012 |
Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Hematologic Tests; Humans; Lenalidomide; Myelodysplastic Syndromes; Remission Induction; Thalidomide; Time Factors; Treatment Outcome | 2011 |
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 17; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Depletion; T-Lymphocytes; Thalidomide | 2011 |
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Risk Factors; Thalidomide; Thrombocytopenia; Transfusion Reaction; Treatment Outcome | 2011 |
Lenalidomide in del 5q MDS: responses and side effects revisited.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide; Transfusion Reaction | 2011 |
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Topics: Amino Acid Substitution; Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Middle Aged; Mutation, Missense; Myelodysplastic Syndromes; Phenylalanine; Thalidomide; Treatment Outcome; Valine | 2011 |
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Humans; Lenalidomide; Myelodysplastic Syndromes; Telomere; Thalidomide | 2012 |
Distinct clonal deletions of the long arm of chromosome 5 in a patient with myelodysplastic syndrome.
Topics: Adjuvants, Immunologic; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Blood Transfusion; Chromosome Deletion; Chromosomes, Artificial, Bacterial; Chromosomes, Human, Pair 5; Clone Cells; Female; Humans; In Situ Hybridization, Fluorescence; Lenalidomide; Thalidomide | 2012 |
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
Topics: Aged; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Myelodysplastic Syndromes; Thalidomide | 2012 |
The 5q- syndrome: biology and treatment.
Topics: Anemia, Macrocytic; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Thalidomide | 2011 |
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Cohort Studies; Disease Progression; Female; France; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Survival Rate; Thalidomide; Treatment Outcome | 2012 |
Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Erythropoiesis; Humans; Lenalidomide; Megakaryocytes; Myelodysplastic Syndromes; Thalidomide | 2012 |
Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases.
Topics: Aged; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2012 |
Establishing Rps6 hemizygous mice as a model for studying how ribosomal protein haploinsufficiency impairs erythropoiesis.
Topics: Agranulocytosis; Alleles; Anemia, Diamond-Blackfan; Anemia, Macrocytic; Animals; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Models, Animal; Erythrocyte Indices; Erythropoiesis; Gene Expression Regulation, Developmental; Hemoglobins; Heterozygote; Lenalidomide; Lymphopenia; Mice; Mice, Inbred C57BL; Prednisone; Ribosomal Protein S6; Ribosomal Proteins; Ribosomes; RNA-Binding Proteins; Thalidomide; Thrombocytosis | 2012 |
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.
Topics: Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA Methyltransferase 3A; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Polymorphism, Single Nucleotide; Prognosis; Thalidomide | 2012 |
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion.
Topics: Animals; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Mice; Myelodysplastic Syndromes; Proto-Oncogene Proteins c-mdm2; Thalidomide; Tumor Suppressor Protein p53; Ubiquitination | 2013 |
Changes associated with lenalidomide treatment in the gene expression profiles of patients with del(5q).
Topics: Actin-Related Protein 2-3 Complex; Aged; Case-Control Studies; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Gene Expression; Humans; Interleukin-1beta; Lenalidomide; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Myelodysplastic Syndromes; Prognosis; Proto-Oncogene Proteins c-jun; Signal Transduction; Stem Cell Niche; Thalidomide; Transcriptome; Tumor Necrosis Factor-alpha; Up-Regulation | 2012 |
Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34(+) cells from patients with del(5q) myelodysplastic syndrome.
Topics: Animals; Antigens, CD34; Chromosome Deletion; Chromosomes, Human, Pair 5; Gene Expression Regulation; Gene Knockdown Techniques; Hematopoietic Stem Cells; Humans; Lenalidomide; Mice; MicroRNAs; Myelodysplastic Syndromes; RNA, Messenger; Thalidomide; Treatment Outcome | 2013 |
Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
Topics: Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Myelodysplastic Syndromes; Netherlands; Thalidomide; Treatment Outcome; White People | 2013 |
Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Erythrocyte Transfusion; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Proportional Hazards Models; Retrospective Studies; Risk; Thalidomide | 2013 |
The 5q- syndrome.
Topics: Age Factors; Antigens, CD; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Erythropoietin; Female; Gene Deletion; Genes, Tumor Suppressor; Humans; Immunosuppressive Agents; Lenalidomide; Male; Myelodysplastic Syndromes; Prognosis; Sex Factors; Thalidomide | 2004 |
Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Karyotyping; Lenalidomide; Middle Aged; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate; Thalidomide | 2005 |
Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome.
Topics: Anemia; Chromosome Deletion; Chromosomes, Human, Pair 5; Contraindications; Female; Humans; Lenalidomide; Myelodysplastic Syndromes; Pregnancy; Pregnancy Complications; Thalidomide; Transfusion Reaction | 2006 |
Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Topics: Acute Disease; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Janus Kinase 2; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Point Mutation; Thalidomide | 2006 |
Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
Topics: Adult; Aged; Chromosome Deletion; Female; Humans; Karyotyping; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome | 2007 |
Treatment of deletion 5q acute myeloid leukemia with lenalidomide.
Topics: Acute Disease; Antineoplastic Agents; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Lenalidomide; Leukemia, Myeloid; Middle Aged; Primary Myelofibrosis; Remission Induction; Thalidomide | 2007 |
Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States.
Topics: Antineoplastic Agents; Blood Transfusion; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 5; Cost-Benefit Analysis; Decision Support Techniques; Erythropoietin; Humans; Lenalidomide; Medical Oncology; Models, Econometric; Myelodysplastic Syndromes; Outcome Assessment, Health Care; Quality-Adjusted Life Years; Recombinant Proteins; Risk Factors; Thalidomide; United States | 2006 |
Practical considerations in the use of lenalidomide therapy for myelodysplastic syndromes.
Topics: Anemia; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Dexamethasone; Drug Therapy, Combination; Humans; Lenalidomide; Medical Oncology; Myelodysplastic Syndromes; Thalidomide | 2006 |
Remitting activity of lenalidomide in treatment-induced myelodysplastic syndrome.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Thalidomide | 2007 |
Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Female; Humans; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Point Mutation; Primary Myelofibrosis; Remission Induction; Thalidomide | 2007 |
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Cell Differentiation; Cells, Cultured; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials, Phase II as Topic; Erythroid Precursor Cells; Erythropoiesis; Gene Expression Profiling; Genetic Markers; Hematopoietic Stem Cells; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Predictive Value of Tests; Thalidomide | 2008 |